ArticleOncotarget2015
miR-200c inhibits breast cancer proliferation by targeting KRAS.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 105 citations in OpenAlex.
- Bioinformatics Analysis of microRNAs Associated with Metastatic Potential in Breast Cancer.Biology · 2026Article
- Role and underlying mechanisms of miR‑200 family in breast cancer (Review).International journal of oncology · 2026Review
- Advances in the study of the breast carcinoma exosomal microRNAs: From basic mechanisms to clinical applications (Review).International journal of oncology · 2026Review
- MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models.BMC cancer · 2026Article
- MicroRNAs: Novel clinical biomarkers for cancer radiotherapy (Review).Molecular medicine reports · 2025Review
- CRISPR/dCas9-TET1-mediated epigenetic editing reactivates miR-200c in breast cancer cells.Scientific reports · 2025Article
- miRNAs Associated with Axillary Lymph Node Metastasis in Breast Cancer: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2025Article
- Unraveling the metastasis-preventing effect of miR-200c in vitro and in vivo.Molecular oncology · 2025Article
- Non-coding RNAs, a double-edged sword in breast cancer prognosis.Cancer cell international · 2025Review
- MicroRNA-200c in Cancer Generation, Invasion, and Metastasis.International journal of molecular sciences · 2025Review
- Review
- Single-cell and machine learning-based pyroptosis-related gene signature predicts prognosis and immunotherapy response in glioblastoma.Frontiers in immunology · 2025Article
- BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients.ACS omega · 2024Article
- Exploring the contrasts: in-depth analysis of human and canine mammary tumors - discoveries at the frontier.Medicine and pharmacy reports · 2024Review
- Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.ACS applied materials & interfaces · 2023Article
- The dynamic tumor-stromal crosstalk: implications of 'stromal-hot' tumors in the process of epithelial-mesenchymal transition in breast cancer.Molecular biology reports · 2023Review
- Unraveling Roles of miR-27b-3p as a Potential Biomarker for Breast Cancer in Malay Women via Bioinformatics Analysis.International journal of molecular and cellular medicine · 2023Article
- Combating Drug Resistance by Exploiting miRNA-200c-Controlled Phase II Detoxification.Cancers · 2022Article
- The role of epigenetic modifications in drug resistance and treatment of breast cancer.Cellular & molecular biology letters · 2022Review
- Prognostic and Predictive Effects of Tumor and Plasma miR-200c-3p in Locally Advanced and Metastatic Breast Cancer.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microRNA, miR-200c, is involved in the tumorigenesis and progression of a variety of cancers. The purpose of this study was to investigate the expression, mechanism and prognostic roles of miR-200c in breast cancer. We found that miR-200c was downregulated in both breast cancer tissue and cell lines using quantitative real-time PCR (qRT-PCR). In situ hybridization (ISH) and microarrays showed that low miR-200c expression was associated with poor patient overall survival (OS) and disease free survival (DFS). We used luciferase reporter plasmids to find that miR-200c inhibited the AKT and ERK pathways by directly targeting KRAS. Repression of KRAS by miR-200c suppressed the proliferation and survival of breast cancer cells in vitro and in vivo. miR-200c also had an anti-tumor effect by negatively regulating KRAS in a xenograft mouse model. Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.